Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01361997
Other study ID # 2011HRAEB001
Secondary ID
Status Completed
Phase Phase 3
First received May 23, 2011
Last updated August 17, 2016
Start date June 2011
Est. completion date August 2012

Study information

Verified date August 2012
Source Universidad de Guanajuato
Contact n/a
Is FDA regulated No
Health authority Mexico: Secretaria de Salud
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determinate if 70% isopropyl alcohol is not inferior preventing contamination of peripheral hemocultures, compared with 2% chlorhexidine in 70% isopropyl alcohol.


Description:

The develop of contaminants in blood cultures is a problem of great impact to health institutions and patients, as they represent a waste of resources, and additionally increases the patient's hospital stay. The principal source of contaminant is the bacteria in the skin flora, so the greatest way to improve the sensibility of this test is to do an optimal skin antisepsis. It has been reported that 2% chlorhexidine gluconate in 70% isopropyl alcohol is superior that other skin disinfectants, and that 70% isopropyl alcohol has a high efficacy reducing the presence of bacteria on the skin, so both antiseptics are good options for skin antisepsis.


Recruitment information / eligibility

Status Completed
Enrollment 1102
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients with suspected blood stream infection.

- Patients allocated in admission, hospitalization and intensive care units.

Exclusion Criteria:

- Patients with a single peripheral hemoculture.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
chlorhexidine in isopropyl alcohol
When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
Isopropyl alcohol
When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.

Locations

Country Name City State
Mexico University of Guanajuato School of Medicine Leon Guanajuato

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Guanajuato

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine if 70% isopropyl alcohol is not inferior preventing contamination of peripheral hemoculture, compared with 2% chlorhexidine in 70% isopropyl alcohol. It will determine the growth of contaminating germs in hemocultures taken with each antiseptic tested. 120 hours Yes
Secondary Determine the rate of contamination of each antiseptic used. It will determine the rate of contamination at the date of primary completion and the date of study completion. We will consider contaminants the development of Staphylococcus coagulase negative and gram positive bacilli. 1 year Yes
Secondary Description of the most frequent bacterial contaminants. It will determine the rate of contamination at the date of primary completion and the date of study completion. We will consider contaminants the development of Staphylococcus coagulase negative and gram positive bacilli. 1 year Yes
See also
  Status Clinical Trial Phase
Completed NCT02763345 - The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi N/A
Completed NCT00550706 - Drug Utilization Prevalence in a Pediatric Care Medical Center N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00761462 - BAY 0 9867 Cipro Pediatric Use Study (QUIP) Phase 3
Completed NCT05088421 - A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers Phase 1
Completed NCT00828971 - A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs Phase 3
Completed NCT05468723 - Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1
Recruiting NCT02162966 - Safety and Efficacy Study of High Dose Colistin Phase 4
Recruiting NCT00001281 - Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
Active, not recruiting NCT02654210 - LoewenKIDS - Infections and the Development of the Immune System
Completed NCT02226263 - Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Phase 2
Terminated NCT00211471 - Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). Phase 2
Active, not recruiting NCT04342702 - A Study on the Prospective Cohort Library of COVID-19 in Southeran
Completed NCT02134548 - Sensitivity Study of Diagnostic for Detection of Chagas Infection N/A
Active, not recruiting NCT01611025 - Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time N/A
Completed NCT00638677 - Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier Phase 4
Completed NCT02434848 - A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses Phase 2/Phase 3
Completed NCT02544139 - Specificity Study of Diagnostic for Chagas Disease N/A
Completed NCT00276198 - Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants Phase 3
Completed NCT02111564 - A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Phase 3